Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of September 2006. The report serves to disclose a material corporate event rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of a strategic agreement and does not contain financial statements.
Material Changes
The primary material change disclosed is the signing of a co-promotion agreement between Sanofi-Aventis and UCB regarding the product Xyzal® in the United States. This agreement was announced via a press release dated September 25, 2006.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the context of the new partnership. The document incorporates the September 25, 2006 press release by reference for further details on the agreement.
Investor Verification Checklist
- Verify the terms and financial implications of the co-promotion agreement for Xyzal® with UCB.
- Review the full text of the press release dated September 25, 2006, referenced as Exhibit 99.1.
- Confirm the regulatory status and market potential of Xyzal® in the United States.